Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis
- 13 June 2023
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (8) , 1013-1022
Abstract
Background Direct oral anticoagulants (DOACs) are associated with bleeding. Patients often stop taking DOACs due to non-major bleeding, which may lead to stroke recurrence. We aimed to determine the risk of non-major bleeding using different DOACs to prevent strokes in atrial fibrillation (AF). Methods A systematic search of four databases (PubMed, EMBASE, Web of Science, and Cochrane Library) was performed to identify randomized controlled trials (RCTs) reporting non-major bleeding events in patients taking DOACs or vitamin K antagonists (VKAs). In this frequency-based network meta-analysis, odds ratios and 95% confidence intervals were used for reporting. Based on the surface under the cumulative ranking curves (SUCRA), the relative ranking probability of each group was generated. Results Nineteen randomized controlled trials (RCTs) (involving 85,826 patients) were included. For clinically relevant non-major bleeding, the risk for bleeding was lowest for apixaban (SUCRA, 93.9), followed by that for VKAs (SUCRA, 47.7), dabigatran (SUCRA, 40.3), rivaroxaban (SUCRA, 35.9), and edoxaban (SUCRA, 32.2). The minor bleeding safety of DOACs was ranked from highest to lowest as follows: apixaban (SUCRA, 78.1), edoxaban (SUCRA, 69.4), dabigatran (SUCRA, 48.8), and VKAs (SUCRA, 3.7). Conclusions Based on current evidence, for stroke prevention in patients with AF, the safest DOAC is apixaban in terms of non-major bleeding. This suggests that apixaban may have a lower risk of non-major bleeding than other anticoagulants and may help provide some clinical reference for choosing a more appropriate drug for the patient.Keywords
Funding Information
- the Science and Technology Innovation Startup Fund of Fujian Maternal and Child Health Hospital (YCXY 23-02, YCXY 23-02, YCXY 23-02, YCXY 23-02)
This publication has 39 references indexed in Scilit:
- Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysisCanadian Journal of Cardiology, 2013
- Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled TrialsCardiovascular Drugs and Therapy, 2012
- Rivaroxaban vs. Warfarin in Japanese Patients With Atrial FibrillationCirculation Journal, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial FibrillationCirculation Journal, 2011
- Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillationThrombosis and Haemostasis, 2011
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachChest, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009